Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 142Myelodysplastic Syndromes 66Leukemia, Myelomonocytic, Chronic 33Neoplasms 17Leukemia 16Recurrence 14Hematologic Neoplasms 14Multiple Myeloma 11Lymphoma, Non-Hodgkin 9Lymphoma 7Carcinoma, Non-Small-Cell Lung 6Primary Myelofibrosis 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 5Neoplasm Metastasis 4Leukemia, Myeloid 4Hodgkin Disease 4Hematologic Diseases 4Prostatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Glioblastoma 3Breast Neoplasms 3Anemia, Refractory, with Excess of Blasts 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Renal Insufficiency 2

Interventions

Azacitidine 2cc-486 1Injections, Subcutaneous 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelomonocytic, Juvenile × Azacitidine × Clear all
NCT00528983 2019-11-08

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Celgene

Phase 1 Completed
133 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Juvenile

NCT02447666 2019-07-11

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Celgene

Phase 2 Completed
28 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡